Cargando…
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
The BIG 1-98 trial is a large, randomized, independently conducted clinical trial designed to compare the efficacy of upfront letrozole versus tamoxifen monotherapy and to compare sequential or up-front use of letrozole and/or tamoxifen as an early adjuvant therapy for patients with early breast can...
Autores principales: | Koeberle, Dieter, Thuerlimann, Beat |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer US
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2001218/ https://www.ncbi.nlm.nih.gov/pubmed/17912636 http://dx.doi.org/10.1007/s10549-007-9700-y |
Ejemplares similares
-
Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
por: Koeberle, Dieter, et al.
Publicado: (2007) -
Interpreting breast international group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer
por: Regan, Meredith M, et al.
Publicado: (2011) -
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor–Positive, Early Breast Cancer
por: Buechler, Steven A, et al.
Publicado: (2019) -
Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor–Positive Metastatic Breast Cancer in Korea
por: Beom, Seung Hoon, et al.
Publicado: (2017) -
Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98
por: Alkner, S., et al.
Publicado: (2017)